ClinicalTrials.gg
CompletedNCT04425902Updated Jan 5, 2024Results posted

Evaluation of Pharmacokinetic Interaction Between GSK3640254 and Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin in Healthy Adults

A Phase 1 interventional study of GSK3640254 200 mg and Caffeine 200 mg in HIV Infections, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies testing GSK3640254 in HIV Infections — none open to participants now, none under way, none of them phase 3. GSK3640254 · HIV Infections.

Enrollment
10th of 15
20 · median 34
Started
2020
with 5 others
Phase 1
12 of 15
none open now
Registered
9th of 15
by date
Lead sponsor
15 of 15
ViiV Healthcare

Among the 15 studies testing GSK3640254 in HIV Infections, this one is the 10th largest by enrollment, is one of 6 that started in 2020, is one of 12 in phase 1, and was the 9th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 15 studies testing GSK3640254 in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About GSK3640254

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies testing GSK3640254 in HIV Infections as a file.
02

Study summary

This is an open-label, single sequence study that is being conducted to investigate the potential drug-drug interaction (DDI) when GSK3640254 is co-administered with a cocktail of cytochrome P450 (CYP) enzymes and transporter probe substrates in healthy participants. This study will aid in understanding these interactions and resulting changes in exposure (if any) when drugs that are metabolized via these pathways are given in combination with GSK3640254. The study will consist of a Screening period and 3 sequential treatment regimens. Participants will be administered a single dose of probe substrate drugs (caffeine 200 milligram (mg), metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg and pravastatin 40 mg) on Day 1. Participants will then receive GSK3640254 200 mg once daily on Days 11 to 20 followed by co-administration of probe substrate drugs with GSK3640254 on Day 21.

03

Conditions studied

  • HIV Infections

Keywords

  • GSK3640254
  • Human immunodeficiency virus (HIV) infections
  • Drug interaction
  • Pharmacokinetics
  • Probe substrate
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 50 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination (including cardiopulmonary examination), laboratory tests, and cardiac monitoring (history and ).
  • Body weight more than or equal to (>=) 50.0 kilograms (kg) (110 pounds [lbs]) for men and >=45.0 kg (99 lbs) for women and within the range 18.5 to 31.0 kilogram per square meter (kg/m\^2) (inclusive).
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Male participants should not engage in intercourse while confined in the clinic. There is no need for an extended period of double barrier use or prolonged abstinence after study discharge.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:
  • Is not a woman of (WOCBP) or
  • Is a WOCBP and using a non-hormonal contraceptive method that is highly effective, with a failure rate of less than (\<) 1 percent (%) for 28 days before intervention, during the intervention period, and for at least 28 days after the last dose of study intervention.
  • A WOCBP must have a negative highly sensitive serum pregnancy test at Screening and check-in (Day-1).
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions, listed in the informed consent form (ICF) and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • A pre-existing condition interfering with normal gastrointestinal (GI) anatomy or motility (e.g., gastro-esophageal reflux disease, gastric ulcers, gastritis) or hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study intervention or render the participant unable to take oral study intervention.
  • Prior cholecystectomy surgery.
  • Any history of significant underlying psychiatric disorder, including, but not limited to, schizophrenia, bipolar disorder with or without psychotic symptoms, other psychotic disorders, or schizotypal (personality) disorder.
  • Any history of major depressive disorder with or without suicidal features, or anxiety disorders that required medical intervention (pharmacologic or not) such as hospitalization or other inpatient treatment and/or chronic (>6 months) outpatient treatment.

Participants with other conditions such as adjustment disorder or dysthymia that have required shorter term medical therapy (\<6 months) without inpatient treatment and are currently well-controlled clinically or resolved may be considered for entry after discussion and agreement with the ViiV Healthcare (VH)/GlaxoSmithKline (GSK) Medical Monitor.

  • Any pre-existing physical or other psychiatric condition (including alcohol or drug abuse), which, in the opinion of the investigator (with or without psychiatric evaluation), could interfere with the participant's ability to comply with the dosing schedule and protocol evaluations or which might compromise the safety of the participant.
  • Medical history of cardiac arrhythmias, prior myocardial infarction in the past 3 months, or cardiac disease or a family or personal history of long syndrome.
  • History of asthma, bronchospasm, or sleep apnea.
  • History of chronic musculoskeletal pain (myalgias).
  • History of rhabdomyolysis.
  • History of a bleeding disorder.
  • History of Raynaud's disease.
  • History indicative of an increased risk of a cardiac arrhythmia or cardiac disease, including the following:
  • History of cardiac arrhythmias or palpitations associated with presyncope or syncope, or history of unexplained syncope.
  • History of cardiac disease including symptomatic or asymptomatic arrhythmias (including but not limited to ventricular fibrillation, ventricular tachycardia, any degree of atrioventricular block, Brugada syndrome, Wolff-Parkinson-White syndrome, and sinus bradycardia, defined as heart rate less than 50 beats per minute (bpm) based on vital signs or ), presyncope or syncopal episodes, or additional risk factors for torsades de pointes (e.g., heart failure).
  • History of clinically relevant structural cardiac disease including hypertrophic obstructive cardiomyopathy.
  • History of hypokalemia.
  • History of heart disease (e.g., coronary heart disease).
  • Presence of surface antigen at Screening or within 3 months prior to starting study intervention.
  • Positive antibody test result at Screening or within 3 months prior to starting study intervention and positive on reflex to hepatitis C Ribonucleic Acid (RNA).
  • Positive -1 and 2 antigen/antibody immunoassay at Screening.
  • >=1.5 × (ULN). A single repeat of ALT is allowed within a single screening period to determine eligibility.
  • >=5 × ULN (isolated bilirubin >=5 × ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). A single repeat of any laboratory abnormality is allowed within a single screening period to determine eligibility.
  • Any acute laboratory abnormality at Screening which, in the opinion of the investigator, should preclude participation in the study of an compound.
  • Any Grade 2 to 4 laboratory abnormality at Screening, with the exception of lipid abnormalities (e.g., total cholesterol, triglycerides), and ALT, will exclude a participant from the study unless the investigator can provide a compelling explanation for the laboratory result(s) and has the assent of the sponsor.
  • A positive test result for drugs of abuse (including marijuana), alcohol, or cotinine (indicating active current smoking) at Screening or before the first dose of study intervention.
  • Unable to refrain from the use of prescription or nonprescription drugs including vitamins, herbal and dietary supplements (including St John's wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study intervention and for the duration of the study.
  • Treatment with any vaccine within 30 days prior to receiving study intervention.
  • Unwillingness to abstain from excessive consumption of any food or drink containing grapefruit and grapefruit juice, Seville oranges, blood oranges, or pomelos or their fruit juices within 7 days prior to the first dose of study intervention(s) until the end of the study.
  • Participation in another concurrent clinical study or prior clinical study (with the exception of imaging trials) prior to the first dosing day in the current study: 30 days, 5 half-lives, or twice the duration of the biological effect of the study intervention (whichever is longer).
  • Prior exposure to GSK3640254 in another clinical study.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 mL within 56 days.
  • Any positive (abnormal) response confirmed by the investigator on a screening clinician- or qualified designee-administered Columbia-Suicide Severity Rating Scale (C-SSRS).
  • SBP \<100 mm Hg. Up to 2 repeats are allowed for confirmation.
  • Any significant arrhythmia or ECG finding (e.g., prior myocardial infarction in the past 3 months, symptomatic bradycardia, non-sustained or sustained atrial arrhythmias, non-sustained or sustained ventricular tachycardia, any degree of atrioventricular block, or conduction abnormality) which will interfere with the safety for the individual participant.
  • Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate- \<50 or >100 bpm, PR interval- >200 milliseconds and QTcF- >450 milliseconds.
  • History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 units. One unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine, or 1 (25 mL) measure of spirits.
  • Unable to refrain from tobacco or nicotine-containing products within 3 months prior to Screening.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  • History of aspirin allergy.
  • A participant with known or suspected active coronavirus disease of 2019 (COVID-19) infection OR contact with an individual with known COVID-19, within 14 days of study enrollment.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Probe Substrates/GSK3640254 200 mg/Probe Substrates+GSK3640254

    All participants will receive a single dose of treatment A: Probe substrates (caffeine 200 milligram \[mg\], metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) on Day 1; followed by treatment B- GSK3640254 200 mg on Days 11 to 20; further followed by treatment C: Probe substrates (Caffeine 200 mg, metoprolol 100 mg, montelukast 10 mg, flurbiprofen 100 mg, omeprazole 40 mg, midazolam 5 mg, digoxin 0.25 mg, and pravastatin 40 mg) co-administered with GSK3640254 200 mg on Day 21.

    Drug: GSK3640254 200 mg · Drug: Caffeine 200 mg · Drug: Metoprolol 100 mg · Drug: Montelukast 10 mg · Drug: Flurbiprofen 100 mg · Drug: Omeprazole 40 mg · Drug: Midazolam 5 mg (2.5 mL) · Drug: Digoxin 0.25 mg · Drug: Pravastatin 40 mg

Interventions

  • GSK3640254 will be available as oral tablets at unit dose strength of 100 mg.

  • Caffeine will be available as oral tablets at unit dose strength of 200 mg.

  • Metoprolol will be available as oral tablets at unit dose strength of 100 mg.

  • Montelukast will be available as oral tablets at unit dose strength of 10 mg.

  • Flurbiprofen will be available as oral tablets at unit dose strength of 100 mg.

  • Omeprazole will be available as oral capsules at unit dose strength of 40 mg.

  • Midazolam will be available as syrup for oral administration at unit dose strength of 2 milligram per milliliter (mg/mL).

  • Digoxin will be available as oral tablet at unit dose strength of 0.25 mg.

  • Pravastatin will be available as oral tablet at unit dose strength of 40 mg.

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  2. AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  3. Maximum Observed Plasma Concentration (Cmax) for Caffeine

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  4. Time to Cmax (Tmax) for Caffeine

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  5. Apparent Terminal Phase Half-life (t1/2) for Caffeine

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  6. AUC(0-t) for Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  7. AUC(0-infinity) for Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  8. Cmax for Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  9. Tmax for Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  10. t1/2 for Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  11. AUC(0-t) for Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  12. AUC(0-infinity) for Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  13. Cmax for Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  14. Tmax for Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  15. t1/2 for Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  16. AUC(0-t) for Flurbiprofen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  17. AUC(0-infinity) for Flurbiprofen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  18. Cmax for Flurbiprofen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  19. Tmax for Flurbiprofen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  20. t1/2 for Flurbiprofen

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  21. AUC(0-t) for Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  22. AUC(0-infinity) for Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  23. Cmax for Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  24. Tmax for Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  25. t1/2 for Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  26. AUC(0-t) for Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  27. AUC(0-infinity) for Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  28. Cmax for Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  29. Tmax for Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  30. t1/2 for Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  31. AUC(0-t) for Digoxin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  32. AUC(0-infinity) for Digoxin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  33. Cmax for Digoxin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  34. Tmax for Digoxin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  35. t1/2 for Digoxin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  36. AUC(0-t) for Pravastatin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  37. AUC(0-infinity) for Pravastatin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  38. Cmax for Pravastatin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  39. Tmax for Pravastatin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  40. t1/2 for Pravastatin

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.

    Time frame: Up to Day 26

  2. Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  3. Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  4. Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  5. Treatment A: Absolute Values of Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  6. Treatment B: Absolute Values of Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  7. Treatment C: Absolute Values of Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  8. Treatment A: Absolute Values of Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  9. Treatment B: Absolute Values of Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  10. Treatment C: Absolute Values of Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  11. Treatment A: Absolute Values of Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  12. Treatment B: Absolute Values of Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  13. Treatment C: Absolute Values of Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  14. Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  15. Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  16. Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  17. Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  18. Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  19. Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  20. Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  21. Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  22. Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  23. Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  24. Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  25. Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  26. Treatment A: Absolute Values of Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  27. Treatment B: Absolute Values of Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  28. Treatment C: Absolute Values of Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  29. Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  30. Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  31. Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  32. Treatment A: Absolute Values of Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

    Time frame: Baseline (Day -1) and Day 10

  33. Treatment B: Absolute Values of Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

    Time frame: Baseline (Day 10) and Day 20

  34. Treatment C: Absolute Values of Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

    Time frame: Baseline (Day 20), Days 22 and 25

  35. Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  36. Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  37. Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

    Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  38. Treatment A: Change From Baseline in Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  39. Treatment B: Change From Baseline in Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  40. Treatment C: Change From Baseline in Hematocrit

    Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  41. Treatment A: Change From Baseline in Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  42. Treatment B: Change From Baseline in Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  43. Treatment C: Change From Baseline in Hemoglobin

    Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  44. Treatment A: Change From Baseline in Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  45. Treatment B: Change From Baseline in Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  46. Treatment C: Change From Baseline in Erythrocytes

    Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  47. Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  48. Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  49. Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  50. Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  51. Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  52. Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  53. Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  54. Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  55. Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

    Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  56. Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  57. Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  58. Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

    Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  59. Treatment A: Change From Baseline in Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  60. Treatment B: Change From Baseline in Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  61. Treatment C: Change From Baseline in Albumin, Globulin, Protein

    Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  62. Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  63. Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  64. Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

    Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  65. Treatment A: Change From Baseline in Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day -1) and Day 10

  66. Treatment B: Change From Baseline in Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 10) and Day 20

  67. Treatment C: Change From Baseline in Amylase, Lipase

    Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 20), Days 22 and 25

  68. Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

    Time frame: Baseline (Day 1, Pre-Dose) and Day 10

  69. Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  70. Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  71. Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  72. Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  73. Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

    Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  74. Treatment A: Absolute Values of Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  75. Treatment B: Absolute Values of Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  76. Treatment C: Absolute Values of Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  77. Treatment A: Absolute Values of Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  78. Treatment B: Absolute Values of Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  79. Treatment C: Absolute Values of Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  80. Treatment A: Absolute Values of Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

    Time frame: Baseline (Day 1, Pre-dose) and Day 2

  81. Treatment B: Absolute Values of Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  82. Treatment C: Absolute Values of Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  83. Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  84. Treatment B: Absolute Values of SBP and DBP

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  85. Treatment C: Absolute Values of SBP and DBP

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  86. Treatment A: Change From Baseline in Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  87. Treatment B: Change From Baseline in Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  88. Treatment C: Change From Baseline in Oral Temperature

    Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  89. Treatment A: Change From Baseline in Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  90. Treatment B: Change From Baseline in Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  91. Treatment C: Change From Baseline in Pulse Rate

    Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  92. Treatment A: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose) and Day 2

  93. Treatment B: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  94. Treatment C: Change From Baseline in Respiratory Rate

    Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  95. Treatment A: Change From Baseline in SBP and DBP

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 1, Pre-dose) and Day 10

  96. Treatment B: Change From Baseline in SBP and DBP

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 11, Pre-Dose) and Day 20

  97. Treatment C: Change From Baseline in SBP and DBP

    SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

    Time frame: Baseline (Day 21, Pre-Dose), Days 22 and 25

  98. Treatment C: AUC(0-t) for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  99. Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  100. Treatment C: Cmax for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  101. Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  102. Treatment C: Tmax for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  103. Treatment C: t1/2 for GSK3640254

    Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

    Time frame: Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3

  104. AUC(0-t) for Alpha-hydroxymetoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  105. AUC(0-infinity) for Alpha-hydroxymetoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  106. Cmax for Alpha-hydroxymetoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  107. Tmax for Alpha-hydroxymetoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  108. t1/2 for Alpha-hydroxymetoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  109. AUC(0-t) for 36-hydroxymontelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  110. AUC(0-infinity) for 36-hydroxymontelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  111. Cmax for 36-hydroxymontelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  112. Tmax for 36-hydroxymontelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  113. t1/2 for 36-hydroxymontelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  114. AUC(0-t) for 5-hydroxyomeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  115. AUC(0-infinity) for 5-hydroxyomeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  116. Cmax for 5-hydroxyomeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  117. Tmax for 5-hydroxyomeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  118. t1/2 for 5-hydroxyomeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  119. AUC(0-t) for 1-hydroxymidazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  120. AUC(0-infinity) for 1-hydroxymidazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  121. Cmax for 1-hydroxymidazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  122. Tmax for 1-hydroxymidazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  123. t1/2 for 1-hydroxymidazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  124. Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  125. Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  126. Ratio of Cmax of 36-hydroxymontelukast to Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  127. Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  128. Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  129. Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  130. Ratio of Cmax of 1-hydroxymidazolam to Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

  131. Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam

    Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

    Time frame: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3

07

Results

Posted May 23, 2022

Participant flow

This study was conducted in the United States.

Treatment Period 1 (Days 1 to 10)
Participant flow — Treatment Period 1 (Days 1 to 10)
MilestoneAll Treated Participants
Started20
Completed20
Not completed0
Treatment Period 2 (Days 11 to 20)
Participant flow — Treatment Period 2 (Days 11 to 20)
MilestoneAll Treated Participants
Started20
Completed19
Not completed1
Withdrew: Adverse event1
Treatment Period 3 (Days 21 to 26)
Participant flow — Treatment Period 3 (Days 21 to 26)
MilestoneAll Treated Participants
Started19
Completed19
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine

Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. Area under the plasma concentration-time curve from time zero to time t, to be calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hour*nanograms per milliliter (h*ng/mL)
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine
Hour*nanograms per milliliter (h*ng/mL)Treatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Area Under the Plasma Concentration-time Curve (AUC) From Time Zero to Time t (AUC[0-t]) for Caffeine37970 ± 31.142230 ± 32.4
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.11 · 90% CI 0.94 to 1.32A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine

Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC From Time Zero Extrapolated to Infinity (AUC[0-infinity]) for Caffeine39720 ± 30.644440 ± 30.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.12 · 90% CI 0.95 to 1.32A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryMaximum Observed Plasma Concentration (Cmax) for Caffeine

Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Caffeine
Nanograms per milliliter (ng/mL)Treatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Maximum Observed Plasma Concentration (Cmax) for Caffeine4340 ± 22.14110 ± 25.9
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.95 · 90% CI 0.83 to 1.08A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTime to Cmax (Tmax) for Caffeine

Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Time to Cmax (Tmax) for Caffeine
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Time to Cmax (Tmax) for Caffeine2.000 (1.00 to 6.00)3.000 (0.50 to 6.00)
PrimaryApparent Terminal Phase Half-life (t1/2) for Caffeine

Blood samples were collected at the indicated time points for pharmacokinetic analysis of caffeine.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
Apparent Terminal Phase Half-life (t1/2) for Caffeine
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Apparent Terminal Phase Half-life (t1/2) for Caffeine5.380 ± 21.26.085 ± 17.4
PrimaryAUC(0-t) for Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Metoprolol
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Metoprolol655.0 ± 135.2807.3 ± 136.4
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.23 · 90% CI 0.71 to 2.14A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Metoprolol
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Metoprolol659.1 ± 134.4813.1 ± 135.3
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.23 · 90% CI 0.71 to 2.14A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Metoprolol
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Metoprolol127.4 ± 90.0141.1 ± 94.4
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.11 · 90% CI 0.72 to 1.69A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Metoprolol
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Metoprolol2.000 (1.00 to 6.00)3.000 (1.00 to 4.00)
Primaryt1/2 for Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Metoprolol
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Metoprolol4.872 ± 65.65.342 ± 59.6
PrimaryAUC(0-t) for Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Montelukast
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Montelukast2724 ± 19.92940 ± 18.4
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.08 · 90% CI 0.97 to 1.20A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Montelukast
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Montelukast2859 ± 20.63109 ± 18.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.09 · 90% CI 0.98 to 1.21A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Nanograms per milliliter (ng/mL)
Cmax for Montelukast
Nanograms per milliliter (ng/mL)Treatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Montelukast379.8 ± 25.2393.5 ± 19.5
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.04 · 90% CI 0.92 to 1.17A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Montelukast
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Montelukast5.000 (2.00 to 8.03)6.000 (3.00 to 8.07)
Primaryt1/2 for Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Montelukast
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Montelukast5.035 ± 10.25.135 ± 7.4
PrimaryAUC(0-t) for Flurbiprofen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Flurbiprofen
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Flurbiprofen64930 ± 28.966170 ± 27.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.02 · 90% CI 0.88 to 1.18A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Flurbiprofen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Flurbiprofen
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Flurbiprofen66700 ± 28.168660 ± 26.7
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.03 · 90% CI 0.89 to 1.19A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Flurbiprofen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Flurbiprofen
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Flurbiprofen10220 ± 24.710710 ± 19.8
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.05 · 90% CI 0.93 to 1.18A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Flurbiprofen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Flurbiprofen
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Flurbiprofen3.000 (1.00 to 8.03)4.000 (1.00 to 6.07)
Primaryt1/2 for Flurbiprofen

Blood samples were collected at the indicated time points for pharmacokinetic analysis of flurbiprofen.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Flurbiprofen
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Flurbiprofen6.123 ± 31.06.088 ± 30.4
PrimaryAUC(0-t) for Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Omeprazole
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Omeprazole728.1 ± 114.7817.9 ± 82.1
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.12 · 90% CI 0.72 to 1.75A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Omeprazole
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Omeprazole1127 ± 98.61093 ± 75.5
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.97 · 90% CI 0.54 to 1.73A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Omeprazole
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Omeprazole224.4 ± 121.6256.6 ± 72.0
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.14 · 90% CI 0.73 to 1.78A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Omeprazole
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Omeprazole6.000 (1.50 to 12.07)6.000 (1.50 to 12.00)
Primaryt1/2 for Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Omeprazole
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Omeprazole1.439 ± 32.01.219 ± 28.1
PrimaryAUC(0-t) for Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Midazolam
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Midazolam67.11 ± 31.362.95 ± 31.0
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.94 · 90% CI 0.80 to 1.11A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Midazolam
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Midazolam70.08 ± 31.465.46 ± 31.2
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.93 · 90% CI 0.79 to 1.10A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Midazolam
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Midazolam15.44 ± 39.513.95 ± 42.3
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.90 · 90% CI 0.73 to 1.12A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Midazolam
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Midazolam1.000 (0.25 to 2.00)1.000 (0.25 to 4.00)
Primaryt1/2 for Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Midazolam
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Midazolam5.756 ± 13.25.222 ± 20.6
PrimaryAUC(0-t) for Digoxin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours*picogram per milliliter (h*pg/mL)
AUC(0-t) for Digoxin
Hours*picogram per milliliter (h*pg/mL)Treatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Digoxin16690 ± 21.717840 ± 26.9
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.07 · 90% CI 0.94 to 1.22A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Digoxin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*pg/mL
AUC(0-infinity) for Digoxin
h*pg/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Digoxin19180 ± 21.520090 ± 27.1
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.05 · 90% CI 0.92 to 1.19A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Digoxin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Picogram per milliliter (pg/mL)
Cmax for Digoxin
Picogram per milliliter (pg/mL)Treatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Digoxin1026 ± 48.31282 ± 56.5
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.25 · 90% CI 0.96 to 1.63A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Digoxin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Digoxin
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Digoxin3.000 (1.50 to 6.00)2.000 (1.00 to 4.00)
Primaryt1/2 for Digoxin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of digoxin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Digoxin
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Digoxin40.279 ± 14.338.784 ± 12.0
PrimaryAUC(0-t) for Pravastatin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Pravastatin
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Pravastatin69.92 ± 63.951.03 ± 75.5
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.73 · 90% CI 0.52 to 1.03A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryAUC(0-infinity) for Pravastatin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Pravastatin
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Pravastatin72.09 ± 62.943.70 ± 47.5
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.61 · 90% CI 0.45 to 0.82A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryCmax for Pravastatin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Pravastatin
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Pravastatin19.45 ± 79.815.19 ± 76.9
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.78 · 90% CI 0.54 to 1.14A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
PrimaryTmax for Pravastatin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Pravastatin
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Pravastatin1.500 (0.50 to 6.00)3.000 (1.00 to 4.00)
Primaryt1/2 for Pravastatin

Blood samples were collected at the indicated time points for pharmacokinetic analysis of pravastatin.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Pravastatin
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Pravastatin3.189 ± 43.43.156 ± 47.2
SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAE was defined as any untoward medical occurrence that, at any dose, results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement.

Time frame:
Up to Day 26
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsTreatment A: Probe SubstratesTreatment B: GSK3640254 200 mgTreatment C: Probe Substrates + GSK3640254 200 mg
AEs155
SAEs000
SecondaryTreatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · 10^9 cells per liter
Treatment A: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment A: Probe Substrates
Baseline (Day -1): Platelet count258.6 ± 59.14
Day 10: Platelet count265.9 ± 60.21
Baseline (Day -1): Leukocyte count5.64 ± 1.338
Day 10: Leukocyte count6.30 ± 1.343
Baseline (Day -1): Neutrophils3.1504 ± 1.25074
Day 10: Neutrophils3.7430 ± 1.27763
Baseline (Day -1): Lymphocytes1.8217 ± 0.39628
Day 10: Lymphocytes1.8965 ± 0.33426
Baseline (Day -1): Monocytes0.4890 ± 0.15889
Day 10: Monocytes0.4515 ± 0.12708
Baseline (Day -1): Eosinophils0.1461 ± 0.15067
Day 10: Eosinophils0.1610 ± 0.15071
Baseline (Day -1): Basophils0.0331 ± 0.01657
Day 10: Basophils0.0440 ± 0.01569
SecondaryTreatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · 10^9 cells per liter
Treatment B: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Platelet count265.9 ± 60.21
Day 20: Platelet count261.9 ± 58.51
Baseline (Day 10): Leukocyte count6.30 ± 1.343
Day 20: Leukocyte count5.79 ± 1.192
Baseline (Day 10): Neutrophils3.7430 ± 1.27763
Day 20: Neutrophils3.2680 ± 1.17833
Baseline (Day 10): Lymphocytes1.8965 ± 0.33426
Day 20: Lymphocytes1.8355 ± 0.52512
Baseline (Day 10): Monocytes0.4515 ± 0.12708
Day 20: Monocytes0.4435 ± 0.16662
Baseline (Day 10): Eosinophils0.1610 ± 0.15071
Day 20: Eosinophils0.1920 ± 0.18981
Baseline (Day 10): Basophils0.0440 ± 0.01569
Day 20: Basophils0.0460 ± 0.02981
SecondaryTreatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · 10^9 cells per liter
Treatment C: Absolute Values of Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Platelet count262.3 ± 60.09
Day 22: Platelet count249.2 ± 51.84
Day 25: Platelet count260.7 ± 54.96
Baseline (Day 20): Leukocyte count5.86 ± 1.184
Day 22: Leukocyte count5.81 ± 1.400
Day 25: Leukocyte count5.98 ± 1.255
Baseline (Day 20): Neutrophils3.3179 ± 1.18871
Day 22: Neutrophils3.1925 ± 1.29353
Day 25: Neutrophils3.4529 ± 1.16823
Baseline (Day 20): Lymphocytes1.8437 ± 0.53820
Day 22: Lymphocytes1.8787 ± 0.57389
Day 25: Lymphocytes1.9280 ± 0.63546
Baseline (Day 20): Monocytes0.4505 ± 0.16811
Day 22: Monocytes0.4689 ± 0.14658
Day 25: Monocytes0.3576 ± 0.12355
Baseline (Day 20): Eosinophils0.1953 ± 0.19443
Day 22: Eosinophils0.2282 ± 0.23748
Day 25: Eosinophils0.1837 ± 0.20635
Baseline (Day 20): Basophils0.0474 ± 0.02997
Day 22: Basophils0.0380 ± 0.02395
Day 25: Basophils0.0408 ± 0.02134
SecondaryTreatment A: Absolute Values of Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Proportion of red blood cells in blood
Treatment A: Absolute Values of Hematocrit
Proportion of red blood cells in bloodTreatment A: Probe Substrates
Baseline (Day -1)0.4188 ± 0.03442
Day 100.4098 ± 0.03577
SecondaryTreatment B: Absolute Values of Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Proportion of red blood cells in blood
Treatment B: Absolute Values of Hematocrit
Proportion of red blood cells in bloodTreatment B: GSK3640254 200 mg
Baseline (Day 10)0.4098 ± 0.03577
Day 200.4216 ± 0.03420
SecondaryTreatment C: Absolute Values of Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Proportion of red blood cells in blood
Treatment C: Absolute Values of Hematocrit
Proportion of red blood cells in bloodTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20)0.4239 ± 0.03352
Day 220.4022 ± 0.04433
Day 250.4168 ± 0.04079
SecondaryTreatment A: Absolute Values of Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Grams per liter
Treatment A: Absolute Values of Hemoglobin
Grams per literTreatment A: Probe Substrates
Baseline (Day -1)141.9 ± 13.27
Day 10137.7 ± 13.07
SecondaryTreatment B: Absolute Values of Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Grams per liter
Treatment B: Absolute Values of Hemoglobin
Grams per literTreatment B: GSK3640254 200 mg
Baseline (Day 10)137.7 ± 13.07
Day 20140.0 ± 12.22
SecondaryTreatment C: Absolute Values of Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Grams per liter
Treatment C: Absolute Values of Hemoglobin
Grams per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20)140.6 ± 12.21
Day 22134.7 ± 15.54
Day 25138.3 ± 13.83
SecondaryTreatment A: Absolute Values of Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · 10^12 cells per liter
Treatment A: Absolute Values of Erythrocytes
10^12 cells per literTreatment A: Probe Substrates
Baseline (Day -1)4.836 ± 0.4125
Day 104.664 ± 0.4459
SecondaryTreatment B: Absolute Values of Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · 10^12 cells per liter
Treatment B: Absolute Values of Erythrocytes
10^12 cells per literTreatment B: GSK3640254 200 mg
Baseline (Day 10)4.664 ± 0.4459
Day 204.746 ± 0.3994
SecondaryTreatment C: Absolute Values of Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · 10^12 cells per liter
Treatment C: Absolute Values of Erythrocytes
10^12 cells per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20)4.769 ± 0.3966
Day 224.608 ± 0.5308
Day 254.756 ± 0.4718
SecondaryTreatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Femtoliter
Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment A: Probe Substrates
Baseline (Day -1)86.71 ± 3.748
Day 1088.02 ± 3.938
SecondaryTreatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Femtoliter
Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment B: GSK3640254 200 mg
Baseline (Day 10)88.02 ± 3.938
Day 2088.96 ± 4.746
SecondaryTreatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Femtoliter
Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20)89.03 ± 4.865
Day 2287.38 ± 4.217
Day 2587.74 ± 4.045
SecondaryTreatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Picograms
Treatment A: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment A: Probe Substrates
Baseline (Day -1)29.37 ± 1.546
Day 1029.57 ± 1.667
SecondaryTreatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Picograms
Treatment B: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment B: GSK3640254 200 mg
Baseline (Day 10)29.57 ± 1.667
Day 2029.52 ± 1.602
SecondaryTreatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Picograms
Treatment C: Absolute Values of Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20)29.51 ± 1.645
Day 2229.28 ± 1.670
Day 2529.12 ± 1.626
SecondaryTreatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Millimoles per liter
Treatment A: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment A: Probe Substrates
Baseline (Day -1): Glucose5.0348 ± 0.37437
Day 10: Glucose4.8211 ± 0.44125
Baseline (Day -1): Carbon Dioxide104.1 ± 2.04
Day 10: Carbon Dioxide25.4 ± 2.11
Baseline (Day -1): Cholesterol4.4570 ± 1.00121
Day 10: Cholesterol3.8118 ± 0.85065
Baseline (Day -1): Triglycerides1.2232 ± 0.51018
Day 10: Triglycerides1.1814 ± 0.82178
Baseline (Day -1): Anion Gap7.9 ± 1.80
Day 10: Anion Gap13.8 ± 1.71
Baseline (Day -1): Calcium2.3765 ± 0.09976
Day 10: Calcium2.3141 ± 0.10267
Baseline (Day -1): Chloride25.8 ± 2.10
Day 10: Chloride103.7 ± 1.81
Baseline (Day -1): Phosphate1.1075 ± 0.16734
Day 10: Phosphate1.1754 ± 0.16141
Baseline (Day -1): Potassium4.48 ± 0.339
Day 10: Potassium4.43 ± 0.256
Baseline (Day -1): Sodium137.7 ± 2.00
Day 10: Sodium138.4 ± 1.93
Baseline (Day -1): Urea4.8195 ± 0.78983
Day 10: Urea5.9458 ± 1.43309
SecondaryTreatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Millimoles per liter
Treatment B: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Glucose4.8211 ± 0.44125
Day 20: Glucose4.7378 ± 0.45996
Baseline (Day 10): Carbon Dioxide25.4 ± 2.11
Day 20: Carbon Dioxide24.9 ± 2.11
Baseline (Day 10): Cholesterol3.8118 ± 0.85065
Day 20: Cholesterol3.6915 ± 0.94881
Baseline (Day 10): Triglycerides1.1814 ± 0.82178
Day 20: Triglycerides1.0825 ± 0.84563
Baseline (Day 10): Anion Gap13.8 ± 1.71
Day 20: Anion Gap14.5 ± 2.12
Baseline (Day 10): Calcium2.3141 ± 0.10267
Day 20: Calcium2.3141 ± 0.08825
Baseline (Day 10): Chloride103.7 ± 1.81
Day 20: Chloride103.6 ± 2.30
Baseline (Day 10): Phosphate1.1754 ± 0.16141
Day 20: Phosphate1.2593 ± 0.13294
Baseline (Day 10): Potassium4.43 ± 0.256
Day 20: Potassium4.39 ± 0.383
Baseline (Day 10): Sodium138.4 ± 1.93
Day 20: Sodium138.6 ± 1.64
Baseline (Day 10): Urea5.9458 ± 1.43309
Day 20: Urea5.6335 ± 1.72537
SecondaryTreatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Millimoles per liter
Treatment C: Absolute Values of Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Glucose4.7184 ± 0.46406
Day 22: Glucose4.8060 ± 0.37890
Day 25: Glucose4.8703 ± 0.40699
Baseline (Day 20): Carbon Dioxide24.9 ± 2.12
Day 22: Carbon Dioxide25.4 ± 1.74
Day 25: Carbon Dioxide26.2 ± 1.80
Baseline (Day 20): Cholesterol3.6898 ± 0.97478
Day 22: Cholesterol3.2543 ± 0.88216
Day 25: Cholesterol3.3972 ± 0.89603
Baseline (Day 20): Triglycerides1.0783 ± 0.86858
Day 22: Triglycerides1.0836 ± 0.78925
Day 25: Triglycerides1.1074 ± 0.81372
Baseline (Day 20): Anion Gap14.6 ± 2.14
Day 22: Anion Gap13.9 ± 1.27
Day 25: Anion Gap14.5 ± 1.95
Baseline (Day 20): Calcium2.3217 ± 0.08377
Day 22: Calcium2.2810 ± 0.10822
Day 25: Calcium2.3519 ± 0.09440
Baseline (Day 20): Chloride103.4 ± 2.22
Day 22: Chloride104.8 ± 2.02
Day 25: Chloride102.6 ± 1.86
Baseline (Day 20): Phosphate1.2661 ± 0.13297
Day 22: Phosphate1.1981 ± 0.14871
Day 25: Phosphate1.3477 ± 0.18638
Baseline (Day 20): Potassium4.38 ± 0.392
Day 22: Potassium4.34 ± 0.347
Day 25: Potassium4.35 ± 0.355
Baseline (Day 20): Sodium138.6 ± 1.67
Day 22: Sodium139.8 ± 1.34
Day 25: Sodium139.0 ± 1.67
Baseline (Day 20): Urea5.7364 ± 1.70835
Day 22: Urea4.9078 ± 1.44100
Day 25: Urea5.3099 ± 1.18355
SecondaryTreatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Micromoles per liter
Treatment A: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment A: Probe Substrates
Baseline (Day -1): Urate347.3632 ± 69.50981
Day 10: Urate365.5046 ± 75.74195
Baseline (Day -1): Creatinine84.9524 ± 19.89935
Day 10: Creatinine86.4110 ± 21.46247
Baseline (Day -1): Bilirubin9.8325 ± 3.13227
Day 10: Bilirubin8.0028 ± 3.01005
Baseline (Day -1): Direct bilirubin2.0520 ± 0.70177
Day 10: Direct bilirubin1.7015 ± 0.63856
SecondaryTreatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Micromoles per liter
Treatment B: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Urate365.5046 ± 75.74195
Day 20: Urate337.8464 ± 76.60060
Baseline (Day 10): Creatinine86.4110 ± 21.46247
Day 20: Creatinine90.7868 ± 22.81174
Baseline (Day 10): Bilirubin8.0028 ± 3.01005
Day 20: Bilirubin8.6184 ± 3.04856
Baseline (Day 10): Direct bilirubin1.7015 ± 0.63856
Day 20: Direct bilirubin1.8126 ± 0.64557
SecondaryTreatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Micromoles per liter
Treatment C: Absolute Values of Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Urate343.1057 ± 74.89791
Day 22: Urate303.0349 ± 71.88291
Day 25: Urate340.6013 ± 67.89995
Baseline (Day 20): Creatinine92.1686 ± 22.56047
Day 22: Creatinine87.3764 ± 22.63812
Day 25: Creatinine90.5867 ± 21.29029
Baseline (Day 20): Bilirubin8.7480 ± 3.07497
Day 22: Bilirubin9.8820 ± 3.24579
Day 25: Bilirubin9.0360 ± 3.89534
Baseline (Day 20): Direct bilirubin1.8450 ± 0.64634
Day 22: Direct bilirubin2.0790 ± 0.60930
Day 25: Direct bilirubin1.9980 ± 0.70286
SecondaryTreatment A: Absolute Values of Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Grams per liter
Treatment A: Absolute Values of Albumin, Globulin, Protein
Grams per literTreatment A: Probe Substrates
Baseline (Day -1): Albumin42.9 ± 2.95
Day 10: Albumin42.2 ± 3.14
Baseline (Day -1): Globulin27.4 ± 3.14
Day 10: Globulin25.9 ± 3.04
Baseline (Day -1): Protein70.3 ± 4.52
Day 10: Protein68.1 ± 3.77
SecondaryTreatment B: Absolute Values of Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Grams per liter
Treatment B: Absolute Values of Albumin, Globulin, Protein
Grams per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Albumin42.2 ± 3.14
Day 20: Albumin41.4 ± 3.31
Baseline (Day 10): Globulin25.9 ± 3.04
Day 20: Globulin26.8 ± 3.58
Baseline (Day 10): Protein68.1 ± 3.77
Day 20: Protein68.2 ± 4.93
SecondaryTreatment C: Absolute Values of Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Grams per liter
Treatment C: Absolute Values of Albumin, Globulin, Protein
Grams per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Albumin41.6 ± 3.24
Day 22: Albumin40.5 ± 3.82
Day 25: Albumin42.0 ± 3.04
Baseline (Day 20): Globulin26.9 ± 3.65
Day 22: Globulin25.1 ± 3.69
Day 25: Globulin26.6 ± 3.67
Baseline (Day 20): Protein68.5 ± 4.85
Day 22: Protein65.6 ± 5.74
Day 25: Protein68.6 ± 4.34
SecondaryTreatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · International units per liter
Treatment A: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transferase
International units per literTreatment A: Probe Substrates
Baseline (Day -1): Creatine kinase103.7 ± 79.68
Day 10: Creatine kinase66.9 ± 34.67
Baseline (Day -1): Lactate dehydrogenase131.3 ± 19.59
Day 10: Lactate dehydrogenase114.8 ± 16.87
Baseline (Day -1): ALT15.6 ± 7.66
Day 10: ALT20.1 ± 14.66
Baseline (Day -1): ALP62.7 ± 18.46
Day 10: ALP60.8 ± 18.03
Baseline (Day -1): AST14.6 ± 3.89
Day 10: AST15.6 ± 5.32
Baseline (Day -1): Gamma-glutamyl transferase19.1 ± 7.16
Day 10: Gamma-glutamyl transferase18.9 ± 8.10
SecondaryTreatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · International units per liter
Treatment B: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Creatine kinase66.9 ± 34.67
Day 20: Creatine kinase68.9 ± 47.98
Baseline (Day 10): Lactate dehydrogenase114.8 ± 16.87
Day 20: Lactate dehydrogenase115.9 ± 17.00
Baseline (Day 10): ALT20.1 ± 14.66
Day 20: ALT20.3 ± 12.38
Baseline (Day 10): ALP60.8 ± 18.03
Day 20: ALP58.5 ± 15.56
Baseline (Day 10): AST15.6 ± 5.32
Day 20: AST16.1 ± 4.80
Baseline (Day 10): Gamma-glutamyl transferase18.9 ± 8.10
Day 20: Gamma-glutamyl transferase18.3 ± 7.69
SecondaryTreatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · International units per liter
Treatment C: Absolute Values of Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Creatine kinase71.3 ± 48.03
Day 22: Creatine kinase65.7 ± 34.56
Day 25: Creatine kinase63.8 ± 30.90
Baseline (Day 20): Lactate dehydrogenase116.6 ± 17.13
Day 22: Lactate dehydrogenase120.6 ± 23.62
Day 25: Lactate dehydrogenase119.3 ± 19.18
Baseline (Day 20): ALT20.4 ± 12.70
Day 22: ALT17.3 ± 9.36
Day 25: ALT20.9 ± 11.92
Baseline (Day 20): ALP58.5 ± 15.98
Day 22: ALP57.6 ± 16.26
Day 25:ALP58.6 ± 16.40
Baseline (Day 20): AST16.2 ± 4.91
Day 22: AST14.7 ± 3.78
Day 25: AST16.4 ± 4.56
Baseline (Day 20): Gamma-glutamyl transferase18.5 ± 7.83
Day 22: Gamma-glutamyl transferase17.1 ± 6.77
Day 25: Gamma-glutamyl transferase18.7 ± 8.23
SecondaryTreatment A: Absolute Values of Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Units per liter
Treatment A: Absolute Values of Amylase, Lipase
Units per literTreatment A: Probe Substrates
Baseline (Day -1): Lipase29.4 ± 14.73
Day 10: Lipase31.6 ± 11.99
Baseline (Day -1): Amylase59.5 ± 22.37
Day 10: Amylase56.9 ± 20.93
SecondaryTreatment B: Absolute Values of Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Units per liter
Treatment B: Absolute Values of Amylase, Lipase
Units per literTreatment B: GSK3640254 200 mg
Baseline (Day 10): Lipase31.6 ± 11.99
Day 20: Lipase32.4 ± 14.51
Baseline (Day 10): Amylase56.9 ± 20.93
Day 20: Amylase60.1 ± 23.22
SecondaryTreatment C: Absolute Values of Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Units per liter
Treatment C: Absolute Values of Amylase, Lipase
Units per literTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 20): Lipase32.9 ± 14.74
Day 22: Lipase33.5 ± 15.19
Day 25: Lipase33.1 ± 14.58
Baseline (Day 20): Amylase62.2 ± 21.79
Day 22: Amylase64.7 ± 25.32
Day 25: Amylase60.7 ± 21.08
SecondaryTreatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · 10^9 cells per liter
Treatment A: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment A: Probe Substrates
Platelet count7.3 ± 20.01
Leukocyte count0.66 ± 0.844
Neutrophils0.5926 ± 0.68577
Lymphocytes0.0748 ± 0.25872
Monocytes-0.0375 ± 0.09379
Eosinophils0.0150 ± 0.07023
Basophils0.0110 ± 0.02138
SecondaryTreatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · 10^9 cells per liter
Treatment B: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment B: GSK3640254 200 mg
Platelet count-4.1 ± 17.31
Leukocyte count-0.51 ± 0.947
Neutrophils-0.4750 ± 0.63752
Lymphocytes-0.0610 ± 0.39045
Monocytes-0.0080 ± 0.11134
Eosinophils0.0310 ± 0.10686
Basophils0.0020 ± 0.02526
SecondaryTreatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils

Blood samples were collected to analyze the hematology parameters: platelet count, leukocyte count, neutrophils, lymphocytes, monocytes, eosinophils and basophils. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · 10^9 cells per liter
Treatment C: Change From Baseline in Platelet Count, Leukocyte Count, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
10^9 cells per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Platelet count-13.1 ± 19.31
Day 25: Platelet count-1.6 ± 24.62
Day 22: Leukocyte count-0.05 ± 0.906
Day 25: Leukocyte count0.12 ± 0.820
Day 22: Neutrophils-0.1254 ± 0.74916
Day 25: Neutrophils0.1351 ± 0.72701
Day 22: Lymphocytes0.0351 ± 0.42962
Day 25: Lymphocytes0.0843 ± 0.41536
Day 22: Monocytes0.0184 ± 0.08808
Day 25: Monocytes-0.0929 ± 0.17694
Day 22: Eosinophils0.0329 ± 0.12007
Day 25: Eosinophils-0.0115 ± 0.06076
Day 22: Basophils-0.0094 ± 0.03787
Day 25: Basophils-0.0066 ± 0.03173
SecondaryTreatment A: Change From Baseline in Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Proportion of red blood cells in blood
Treatment A: Change From Baseline in Hematocrit
Proportion of red blood cells in bloodTreatment A: Probe Substrates
Treatment A: Change From Baseline in Hematocrit-0.0090 ± 0.02082
SecondaryTreatment B: Change From Baseline in Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Proportion of red blood cells in blood
Treatment B: Change From Baseline in Hematocrit
Proportion of red blood cells in bloodTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Hematocrit0.0118 ± 0.01667
SecondaryTreatment C: Change From Baseline in Hematocrit

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Proportion of red blood cells in blood
Treatment C: Change From Baseline in Hematocrit
Proportion of red blood cells in bloodTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-0.0217 ± 0.02090
Day 25-0.0071 ± 0.02129
SecondaryTreatment A: Change From Baseline in Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Grams per liter
Treatment A: Change From Baseline in Hemoglobin
Grams per literTreatment A: Probe Substrates
Treatment A: Change From Baseline in Hemoglobin-4.2 ± 6.34
SecondaryTreatment B: Change From Baseline in Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Grams per liter
Treatment B: Change From Baseline in Hemoglobin
Grams per literTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Hemoglobin2.3 ± 4.91
SecondaryTreatment C: Change From Baseline in Hemoglobin

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Grams per liter
Treatment C: Change From Baseline in Hemoglobin
Grams per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-5.8 ± 6.52
Day 25-2.3 ± 5.82
SecondaryTreatment A: Change From Baseline in Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · 10^12 cells per liter
Treatment A: Change From Baseline in Erythrocytes
10^12 cells per literTreatment A: Probe Substrates
Treatment A: Change From Baseline in Erythrocytes-0.172 ± 0.2219
SecondaryTreatment B: Change From Baseline in Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · 10^12 cells per liter
Treatment B: Change From Baseline in Erythrocytes
10^12 cells per literTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Erythrocytes0.083 ± 0.1768
SecondaryTreatment C: Change From Baseline in Erythrocytes

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · 10^12 cells per liter
Treatment C: Change From Baseline in Erythrocytes
10^12 cells per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-0.161 ± 0.2190
Day 25-0.013 ± 0.2027
SecondaryTreatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Femtoliter
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment A: Probe Substrates
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Volume1.31 ± 1.539
SecondaryTreatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Femtoliter
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Volume0.94 ± 2.519
SecondaryTreatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Femtoliter
Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Volume
FemtoliterTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-1.64 ± 1.849
Day 25-1.28 ± 2.234
SecondaryTreatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Picograms
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment A: Probe Substrates
Treatment A: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin0.20 ± 0.352
SecondaryTreatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Picograms
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin-0.05 ± 0.298
SecondaryTreatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Picograms
Treatment C: Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin
PicogramsTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-0.23 ± 0.407
Day 25-0.39 ± 0.519
SecondaryTreatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Millimoles per liter
Treatment A: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment A: Probe Substrates
Glucose-0.2137 ± 0.29663
Carbon Dioxide-78.7 ± 3.12
Cholesterol-0.6452 ± 0.47501
Triglycerides-0.0418 ± 0.59458
Anion Gap5.9 ± 2.21
Calcium-0.0624 ± 0.04889
Chloride78.0 ± 2.98
Phosphate0.0678 ± 0.10522
Potassium-0.05 ± 0.402
Sodium0.7 ± 2.16
Urea1.1263 ± 0.97483
SecondaryTreatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium, and urea. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Millimoles per liter
Treatment B: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment B: GSK3640254 200 mg
Glucose-0.0833 ± 0.29345
Carbon Dioxide-0.6 ± 1.79
Cholesterol-0.1203 ± 0.30774
Triglycerides-0.0989 ± 0.30531
Anion Gap0.8 ± 1.94
Calcium0.0000 ± 0.06575
Chloride-0.1 ± 1.52
Phosphate0.0840 ± 0.08601
Potassium-0.05 ± 0.378
Sodium0.3 ± 1.41
Urea-0.3124 ± 0.72202
SecondaryTreatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea

Blood samples were collected to analyze the chemistry parameters: glucose, carbon dioxide, cholesterol, triglycerides, anion gap, calcium, chloride, phosphate, potassium, sodium and urea. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Millimoles per liter
Treatment C: Change From Baseline in Glucose, Carbon Dioxide, Cholesterol, Triglycerides, Anion Gap, Calcium, Chloride, Phosphate, Potassium, Sodium, Urea
Millimoles per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Glucose0.0876 ± 0.29392
Day 25: Glucose0.1519 ± 0.32570
Day 22: Carbon Dioxide0.5 ± 2.12
Day 25: Carbon Dioxide1.2 ± 1.81
Day 22: Cholesterol-0.4355 ± 0.31287
Day 25: Cholesterol-0.2926 ± 0.25147
Day 22: Triglycerides0.0054 ± 0.14595
Day 25: Triglycerides0.0291 ± 0.18280
Day 22: Anion Gap-0.6 ± 1.80
Day 25: Anion Gap-0.1 ± 0.97
Day 22: Calcium-0.0407 ± 0.07165
Day 25: Calcium0.0302 ± 0.05553
Day 22: Chloride1.4 ± 1.64
Day 25: Chloride-0.8 ± 1.78
Day 22: Phosphate-0.0680 ± 0.09860
Day 25: Phosphate0.0816 ± 0.09527
Day 22: Potassium-0.04 ± 0.373
Day 25: Potassium-0.03 ± 0.441
Day 22: Sodium1.2 ± 1.51
Day 25: Sodium0.4 ± 2.41
Day 22: Urea-0.8286 ± 0.88169
Day 25: Urea-0.4265 ± 0.85981
SecondaryTreatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Micromoles per liter
Treatment A: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment A: Probe Substrates
Urate18.1414 ± 39.28786
Creatinine1.4586 ± 5.65145
Bilirubin-1.8297 ± 1.38266
Direct bilirubin-0.3506 ± 0.60895
SecondaryTreatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Micromoles per liter
Treatment B: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment B: GSK3640254 200 mg
Urate-27.6582 ± 25.47573
Creatinine4.3758 ± 4.38239
Bilirubin0.6156 ± 1.92059
Direct bilirubin0.1112 ± 0.46509
SecondaryTreatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin

Blood samples were collected to analyze the chemistry parameters: urate, creatinine, bilirubin and direct bilirubin. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Micromoles per liter
Treatment C: Change From Baseline in Urate, Creatinine, Bilirubin, Direct Bilirubin
Micromoles per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Urate-40.0707 ± 26.51457
Day 25: Urate-2.5044 ± 26.62359
Day 22: Creatinine-4.7922 ± 5.82901
Day 25: Creatinine-1.5819 ± 4.60830
Day 22: Bilirubin1.1340 ± 1.91202
Day 25: Bilirubin0.2880 ± 2.14494
Day 22: Direct bilirubin0.2340 ± 0.38326
Day 25: Direct bilirubin0.1530 ± 0.39447
SecondaryTreatment A: Change From Baseline in Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Grams per liter
Treatment A: Change From Baseline in Albumin, Globulin, Protein
Grams per literTreatment A: Probe Substrates
Albumin-0.7 ± 1.75
Globulin-1.5 ± 1.61
Protein-2.2 ± 2.57
SecondaryTreatment B: Change From Baseline in Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Grams per liter
Treatment B: Change From Baseline in Albumin, Globulin, Protein
Grams per literTreatment B: GSK3640254 200 mg
Albumin-0.9 ± 2.43
Globulin0.9 ± 2.07
Protein0.1 ± 3.71
SecondaryTreatment C: Change From Baseline in Albumin, Globulin, Protein

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Grams per liter
Treatment C: Change From Baseline in Albumin, Globulin, Protein
Grams per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Albumin-1.1 ± 2.44
Day 25: Albumin0.4 ± 1.71
Day 22: Globulin-1.8 ± 1.98
Day 25: Globulin-0.3 ± 1.76
Day 22: Protein-2.9 ± 4.15
Day 25: Protein0.2 ± 2.81
SecondaryTreatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST and gamma-glutamyl transferase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · International units per liter
Treatment A: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literTreatment A: Probe Substrates
Creatine kinase-36.9 ± 59.38
Lactate dehydrogenase-16.5 ± 15.50
ALT4.5 ± 11.51
ALP-1.9 ± 6.39
AST1.0 ± 4.52
Gamma-glutamyl transferase-0.2 ± 3.86
SecondaryTreatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, and gamma-glutamyl transferase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · International units per liter
Treatment B: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literTreatment B: GSK3640254 200 mg
Creatine kinase2.1 ± 24.48
Lactate dehydrogenase1.1 ± 13.15
ALT0.3 ± 6.78
ALP-2.4 ± 6.21
AST0.6 ± 3.03
Gamma-glutamyl transferase-0.6 ± 2.74
SecondaryTreatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase

Blood samples were collected to analyze the chemistry parameters: creatine kinase, lactate dehydrogenase, ALT, ALP, AST, gamma-glutamyl transferase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · International units per liter
Treatment C: Change From Baseline in Creatine Kinase, Lactate Dehydrogenase, ALT, ALP, AST, Gamma-glutamyl Transferase
International units per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Creatine kinase-5.6 ± 21.78
Day 25: Creatine kinase-7.5 ± 26.10
Day 22: Lactate dehydrogenase4.0 ± 18.94
Day 25: Lactate dehydrogenase2.6 ± 16.30
Day 22: ALT-3.1 ± 4.12
Day 25: ALT0.5 ± 2.61
Day 22: ALP-0.9 ± 5.83
Day 25:ALP0.1 ± 3.91
Day 22: AST-1.5 ± 2.78
Day 25: AST0.2 ± 1.89
Day 22: Gamma-glutamyl transferase-1.5 ± 1.61
Day 25: Gamma-glutamyl transferase0.2 ± 1.26
SecondaryTreatment A: Change From Baseline in Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day -1), before the dose of Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day -1) and Day 10
Reported as:
Mean · Units per liter
Treatment A: Change From Baseline in Amylase, Lipase
Units per literTreatment A: Probe Substrates
Lipase2.2 ± 6.81
Amylase-2.6 ± 7.86
SecondaryTreatment B: Change From Baseline in Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 10), before the first dose of Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 10) and Day 20
Reported as:
Mean · Units per liter
Treatment B: Change From Baseline in Amylase, Lipase
Units per literTreatment B: GSK3640254 200 mg
Lipase0.9 ± 6.07
Amylase3.2 ± 6.31
SecondaryTreatment C: Change From Baseline in Amylase, Lipase

Blood samples were collected to analyze the chemistry parameters: amylase and lipase. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 20), before the dose of Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 20), Days 22 and 25
Reported as:
Mean · Units per liter
Treatment C: Change From Baseline in Amylase, Lipase
Units per literTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: Lipase0.6 ± 10.08
Day 25: Lipase0.2 ± 4.88
Day 22: Amylase2.5 ± 7.10
Day 25: Amylase-1.5 ± 4.98
SecondaryTreatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

Time frame:
Baseline (Day 1, Pre-Dose) and Day 10
Reported as:
Mean · Milliseconds
Treatment A: Absolute Values for Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval, Corrected QT Interval Using Fridericia's Formula (QTcF)
MillisecondsTreatment A: Probe Substrates
Baseline (Day 1, Pre-dose): PR Interval154.8 ± 20.92
Day 10: PR Interval158.2 ± 22.67
Baseline (Day 1, Pre-dose): QRS Duration92.5 ± 8.34
Day 10: QRS Duration95.0 ± 10.11
Baseline (Day 1, Pre-dose): QT Interval391.2 ± 22.41
Day 10: QT Interval398.3 ± 22.19
Baseline (Day 1, Pre-dose): QTcF Interval401.0 ± 16.48
Day 10: QTcF Interval405.8 ± 16.25
SecondaryTreatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Milliseconds
Treatment B: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
MillisecondsTreatment B: GSK3640254 200 mg
Baseline (Day 11, Pre-dose): PR Interval158.6 ± 19.44
Day 20: PR Interval161.8 ± 22.40
Baseline (Day 11, Pre-dose): QRS Duration94.2 ± 8.73
Day 20: QRS Duration96.4 ± 9.25
Baseline (Day 11, Pre-dose): QT Interval403.1 ± 26.27
Day 20: QT Interval408.8 ± 25.85
Baseline (Day 11, Pre-dose): QTcF Interval403.5 ± 17.63
Day 20: QTcF Interval408.6 ± 17.26
SecondaryTreatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Milliseconds
Treatment C: Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF Interval
MillisecondsTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 21, Pre-dose): PR Interval160.8 ± 20.26
Day 22: PR Interval162.3 ± 22.07
Day 25: PR Interval159.6 ± 23.55
Baseline (Day 21, Pre-dose): QRS Duration95.8 ± 9.49
Day 22: QRS Duration98.7 ± 10.30
Day 25: QRS Duration96.8 ± 8.42
Baseline (Day 21, Pre-dose): QT Interval402.6 ± 21.06
Day 22: QT Interval420.6 ± 21.16
Day 25: QT Interval398.7 ± 22.25
Baseline (Day 21, Pre-dose): QTcF Interval408.7 ± 16.31
Day 22: QTcF Interval407.3 ± 13.75
Day 25: QTcF Interval402.5 ± 17.03
SecondaryTreatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Milliseconds
Treatment A: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
MillisecondsTreatment A: Probe Substrates
PR Interval3.4 ± 9.28
QRS Duration2.5 ± 4.37
QT Interval7.1 ± 12.81
QTcF Interval4.8 ± 9.27
SecondaryTreatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Milliseconds
Treatment B: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
MillisecondsTreatment B: GSK3640254 200 mg
PR Interval3.2 ± 8.79
QRS Duration2.3 ± 2.77
QT Interval5.7 ± 13.30
QTcF Interval5.1 ± 10.69
SecondaryTreatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF

Twelve-lead ECGs were obtained to measure PR Interval, QRS Duration, QT Interval and QTcF Interval. Twelve-lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Milliseconds
Treatment C: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval, QTcF
MillisecondsTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: PR Interval1.5 ± 9.99
Day 25: PR Interval-1.2 ± 10.07
Day 22: QRS Duration2.9 ± 4.24
Day 25: QRS Duration1.0 ± 3.43
Day 22: QT Interval18.0 ± 20.32
Day 25: QT Interval-3.9 ± 16.18
Day 22: QTcF Interval-1.4 ± 9.44
Day 25: QTcF Interval-6.3 ± 8.41
SecondaryTreatment A: Absolute Values of Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Degrees Celsius
Treatment A: Absolute Values of Oral Temperature
Degrees CelsiusTreatment A: Probe Substrates
Baseline (Day 1, Pre-dose)36.38 ± 0.293
Day 1036.26 ± 0.252
SecondaryTreatment B: Absolute Values of Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Degrees Celsius
Treatment B: Absolute Values of Oral Temperature
Degrees CelsiusTreatment B: GSK3640254 200 mg
Baseline (Day 11, Pre-dose)36.31 ± 0.320
Day 2036.28 ± 0.246
SecondaryTreatment C: Absolute Values of Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Degrees Celsius
Treatment C: Absolute Values of Oral Temperature
Degrees CelsiusTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 21, Pre-dose)36.31 ± 0.284
Day 2236.18 ± 0.210
Day 2536.31 ± 0.300
SecondaryTreatment A: Absolute Values of Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Beats per minute
Treatment A: Absolute Values of Pulse Rate
Beats per minuteTreatment A: Probe Substrates
Baseline (Day 1, Pre-dose)64.5 ± 8.97
Day 1065.0 ± 8.19
SecondaryTreatment B: Absolute Values of Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Beats per minute
Treatment B: Absolute Values of Pulse Rate
Beats per minuteTreatment B: GSK3640254 200 mg
Baseline (Day 11, Pre-dose)61.6 ± 9.95
Day 2062.8 ± 10.22
SecondaryTreatment C: Absolute Values of Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Beats per minute
Treatment C: Absolute Values of Pulse Rate
Beats per minuteTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 21, Pre-dose)63.2 ± 7.04
Day 2256.2 ± 6.83
Day 2561.7 ± 7.27
SecondaryTreatment A: Absolute Values of Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

Time frame:
Baseline (Day 1, Pre-dose) and Day 2
Reported as:
Mean · Breaths per minute
Treatment A: Absolute Values of Respiratory Rate
Breaths per minuteTreatment A: Probe Substrates
Baseline (Day 1, Pre-dose)16.1 ± 1.37
Day 215.8 ± 2.33
SecondaryTreatment B: Absolute Values of Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Breaths per minute
Treatment B: Absolute Values of Respiratory Rate
Breaths per minuteTreatment B: GSK3640254 200 mg
Baseline (Day 11, Pre-dose)15.0 ± 2.29
Day 2014.7 ± 2.27
SecondaryTreatment C: Absolute Values of Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Breaths per minute
Treatment C: Absolute Values of Respiratory Rate
Breaths per minuteTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 21, Pre-dose)15.7 ± 1.56
Day 2215.7 ± 1.38
Day 2516.5 ± 2.20
SecondaryTreatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Millimeters of mercury
Treatment A: Absolute Values of Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryTreatment A: Probe Substrates
Baseline (Day 1, Pre-dose): SBP111.0 ± 9.03
Day 10: SBP107.7 ± 9.32
Baseline (Day 1, Pre-dose): DBP65.1 ± 6.73
Day 10: DBP59.7 ± 6.24
SecondaryTreatment B: Absolute Values of SBP and DBP

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Millimeters of mercury
Treatment B: Absolute Values of SBP and DBP
Millimeters of mercuryTreatment B: GSK3640254 200 mg
Baseline (Day 11, Pre-dose): SBP107.7 ± 8.46
Day 20: SBP107.2 ± 9.52
Baseline (Day 11, Pre-dose): DBP61.6 ± 6.56
Day 20: DBP59.6 ± 5.55
SecondaryTreatment C: Absolute Values of SBP and DBP

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Millimeters of mercury
Treatment C: Absolute Values of SBP and DBP
Millimeters of mercuryTreatment C: Probe Substrates + GSK3640254 200 mg
Baseline (Day 21, Pre-dose): SBP107.5 ± 8.49
Day 22: SBP105.6 ± 11.93
Day 25: SBP109.7 ± 7.96
Baseline (Day 21, Pre-dose): DBP62.7 ± 5.31
Day 22: DBP58.4 ± 5.87
Day 25: DBP62.2 ± 5.06
SecondaryTreatment A: Change From Baseline in Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Degrees Celsius
Treatment A: Change From Baseline in Oral Temperature
Degrees CelsiusTreatment A: Probe Substrates
Treatment A: Change From Baseline in Oral Temperature-0.12 ± 0.314
SecondaryTreatment B: Change From Baseline in Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Degrees Celsius
Treatment B: Change From Baseline in Oral Temperature
Degrees CelsiusTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Oral Temperature-0.03 ± 0.249
SecondaryTreatment C: Change From Baseline in Oral Temperature

Oral temperature was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Degrees Celsius
Treatment C: Change From Baseline in Oral Temperature
Degrees CelsiusTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-0.13 ± 0.242
Day 250.01 ± 0.286
SecondaryTreatment A: Change From Baseline in Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Beats per minute
Treatment A: Change From Baseline in Pulse Rate
Beats per minuteTreatment A: Probe Substrates
Treatment A: Change From Baseline in Pulse Rate0.5 ± 6.27
SecondaryTreatment B: Change From Baseline in Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Beats per minute
Treatment B: Change From Baseline in Pulse Rate
Beats per minuteTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Pulse Rate1.3 ± 7.44
SecondaryTreatment C: Change From Baseline in Pulse Rate

Pulse rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Beats per minute
Treatment C: Change From Baseline in Pulse Rate
Beats per minuteTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-7.1 ± 7.48
Day 25-1.5 ± 6.17
SecondaryTreatment A: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose) and Day 2
Reported as:
Mean · Breaths per minute
Treatment A: Change From Baseline in Respiratory Rate
Breaths per minuteTreatment A: Probe Substrates
Treatment A: Change From Baseline in Respiratory Rate-0.3 ± 2.62
SecondaryTreatment B: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Breaths per minute
Treatment B: Change From Baseline in Respiratory Rate
Breaths per minuteTreatment B: GSK3640254 200 mg
Treatment B: Change From Baseline in Respiratory Rate-0.3 ± 2.36
SecondaryTreatment C: Change From Baseline in Respiratory Rate

Respiratory rate was measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Breaths per minute
Treatment C: Change From Baseline in Respiratory Rate
Breaths per minuteTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22-0.1 ± 1.90
Day 250.8 ± 2.37
SecondaryTreatment A: Change From Baseline in SBP and DBP

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment A was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 1, Pre-Dose), before the dose in Treatment A. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 1, Pre-dose) and Day 10
Reported as:
Mean · Millimeters of mercury
Treatment A: Change From Baseline in SBP and DBP
Millimeters of mercuryTreatment A: Probe Substrates
SBP-3.3 ± 9.67
DBP-5.4 ± 5.96
SecondaryTreatment B: Change From Baseline in SBP and DBP

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment B was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 11, Pre-Dose), before the first dose in Treatment B. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 11, Pre-Dose) and Day 20
Reported as:
Mean · Millimeters of mercury
Treatment B: Change From Baseline in SBP and DBP
Millimeters of mercuryTreatment B: GSK3640254 200 mg
SBP-0.5 ± 8.56
DBP-2.0 ± 5.75
SecondaryTreatment C: Change From Baseline in SBP and DBP

SBP and DBP were measured in the supine position after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline for treatment C was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits (Day 21, Pre-Dose), before the first dose in Treatment C. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Time frame:
Baseline (Day 21, Pre-Dose), Days 22 and 25
Reported as:
Mean · Millimeters of mercury
Treatment C: Change From Baseline in SBP and DBP
Millimeters of mercuryTreatment C: Probe Substrates + GSK3640254 200 mg
Day 22: SBP-1.9 ± 10.84
Day 25: SBP2.2 ± 8.67
Day 22: DBP-4.3 ± 4.75
Day 25: DBP-0.5 ± 4.78
SecondaryTreatment C: AUC(0-t) for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Geometric mean · h*ng/mL
Treatment C: AUC(0-t) for GSK3640254
h*ng/mLTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: AUC(0-t) for GSK364025451840 ± 48.8
SecondaryTreatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Geometric mean · h*ng/mL
Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK3640254
h*ng/mLTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: AUC From Time Zero to the End of the Dosing Interval at Steady State (AUC[0-tau]) for GSK364025422920 ± 37.3
SecondaryTreatment C: Cmax for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Geometric mean · ng/mL
Treatment C: Cmax for GSK3640254
ng/mLTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: Cmax for GSK36402541450 ± 41.7
SecondaryTreatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Geometric mean · ng/mL
Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254
ng/mLTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: Plasma Concentration at the End of the Dosing Interval (Ctau) for GSK3640254729.5 ± 35.5
SecondaryTreatment C: Tmax for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Median · Hours
Treatment C: Tmax for GSK3640254
HoursTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: Tmax for GSK36402544.500 (2.00 to 8.03)
SecondaryTreatment C: t1/2 for GSK3640254

Blood samples were collected at the indicated time points for steady-state pharmacokinetic analysis of GSK3640254.

Time frame:
Pre-dose and at 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose in treatment period 3
Reported as:
Geometric mean · Hours
Treatment C: t1/2 for GSK3640254
HoursTreatment C: Probe Substrates + GSK3640254 200 mg
Treatment C: t1/2 for GSK364025429.556 ± 16.9
SecondaryAUC(0-t) for Alpha-hydroxymetoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for Alpha-hydroxymetoprolol
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for Alpha-hydroxymetoprolol531.3 ± 159.4487.9 ± 174.4
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.92 · 90% CI 0.49 to 1.71A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryAUC(0-infinity) for Alpha-hydroxymetoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for Alpha-hydroxymetoprolol
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for Alpha-hydroxymetoprolol682.8 ± 34.1632.8 ± 50.7
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.93 · 90% CI 0.74 to 1.16A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryCmax for Alpha-hydroxymetoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for Alpha-hydroxymetoprolol
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for Alpha-hydroxymetoprolol45.70 ± 199.839.21 ± 212.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.86 · 90% CI 0.43 to 1.72A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryTmax for Alpha-hydroxymetoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for Alpha-hydroxymetoprolol
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for Alpha-hydroxymetoprolol3.033 (1.00 to 6.00)4.000 (1.00 to 8.00)
Secondaryt1/2 for Alpha-hydroxymetoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of alpha-hydroxymetoprolol. Alpha-hydroxymetoprolol is a metabolite of metoprolol.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for Alpha-hydroxymetoprolol
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for Alpha-hydroxymetoprolol8.040 ± 31.48.339 ± 23.0
SecondaryAUC(0-t) for 36-hydroxymontelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukas. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for 36-hydroxymontelukast
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for 36-hydroxymontelukast234.2 ± 47.2230.9 ± 59.1
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.99 · 90% CI 0.75 to 1.29A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryAUC(0-infinity) for 36-hydroxymontelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for 36-hydroxymontelukast
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for 36-hydroxymontelukast252.5 ± 48.2249.3 ± 58.7
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.99 · 90% CI 0.75 to 1.29A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryCmax for 36-hydroxymontelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for 36-hydroxymontelukast
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for 36-hydroxymontelukast24.62 ± 45.723.22 ± 55.0
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.94 · 90% CI 0.73 to 1.22A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryTmax for 36-hydroxymontelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for 36-hydroxymontelukast
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for 36-hydroxymontelukast6.000 (3.00 to 8.03)6.000 (4.00 to 8.13)
Secondaryt1/2 for 36-hydroxymontelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 36-hydroxymontelukast. 36-hydroxymontelukast is a metabolite of montelukast.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for 36-hydroxymontelukast
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for 36-hydroxymontelukast5.310 ± 14.35.644 ± 15.1
SecondaryAUC(0-t) for 5-hydroxyomeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for 5-hydroxyomeprazole
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for 5-hydroxyomeprazole713.5 ± 38.0785.1 ± 24.7
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.10 · 90% CI 0.93 to 1.30A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryAUC(0-infinity) for 5-hydroxyomeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for 5-hydroxyomeprazole
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for 5-hydroxyomeprazole767.4 ± 30.9762.0 ± 25.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.99 · 90% CI 0.83 to 1.19A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryCmax for 5-hydroxyomeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for 5-hydroxyomeprazole
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for 5-hydroxyomeprazole181.1 ± 63.1203.3 ± 28.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 1.12 · 90% CI 0.88 to 1.44A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryTmax for 5-hydroxyomeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for 5-hydroxyomeprazole
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for 5-hydroxyomeprazole6.000 (2.05 to 12.07)6.000 (1.50 to 12.00)
Secondaryt1/2 for 5-hydroxyomeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 5-hydroxyomeprazole. 5-hydroxyomeprazole is a metabolite of omeprazole.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for 5-hydroxyomeprazole
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for 5-hydroxyomeprazole1.580 ± 15.41.569 ± 13.5
SecondaryAUC(0-t) for 1-hydroxymidazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-t) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-t) for 1-hydroxymidazolam
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-t) for 1-hydroxymidazolam31.07 ± 33.028.07 ± 37.0
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.90 · 90% CI 0.75 to 1.09A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryAUC(0-infinity) for 1-hydroxymidazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam. The AUC(0-infinity) was determined using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · h*ng/mL
AUC(0-infinity) for 1-hydroxymidazolam
h*ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
AUC(0-infinity) for 1-hydroxymidazolam31.86 ± 32.528.99 ± 36.6
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.91 · 90% CI 0.76 to 1.09A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryCmax for 1-hydroxymidazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · ng/mL
Cmax for 1-hydroxymidazolam
ng/mLTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Cmax for 1-hydroxymidazolam7.933 ± 53.86.722 ± 48.1
Statistical analysis
  • Treatment A: Probe Substrates vs Treatment C: Probe Substrates + GSK3640254 200 mg · Ratio of geometric least square mean: 0.85 · 90% CI 0.65 to 1.10A mixed-effect model with treatment as a fixed effect and measurements within participant as repeated measures was performed on the natural ln-transformed parameter.
SecondaryTmax for 1-hydroxymidazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Median · Hours
Tmax for 1-hydroxymidazolam
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Tmax for 1-hydroxymidazolam1.000 (0.25 to 3.00)1.000 (0.25 to 4.00)
Secondaryt1/2 for 1-hydroxymidazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of 1-hydroxymidazolam. 1-hydroxymidazolam is a metabolite of midazolam.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Geometric mean · Hours
t1/2 for 1-hydroxymidazolam
HoursTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
t1/2 for 1-hydroxymidazolam3.632 ± 15.63.717 ± 21.0
SecondaryRatio of Cmax of Alpha-hydroxymetoprolol to Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of Cmax of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of Cmax of Alpha-hydroxymetoprolol to Metoprolol0.7869 ± 0.768960.7066 ± 0.93732
SecondaryRatio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (metoprolol) and its metabolite (alpha-hydroxymetoprolol). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of AUC(0-infinity) of Alpha-hydroxymetoprolol to Metoprolol1.733 ± 1.62081.449 ± 1.6511
SecondaryRatio of Cmax of 36-hydroxymontelukast to Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of Cmax of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of Cmax of 36-hydroxymontelukast to Montelukast
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of Cmax of 36-hydroxymontelukast to Montelukast0.06766 ± 0.0250680.06308 ± 0.025951
SecondaryRatio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (montelukast) and its metabolite (36-hydroxymontelukast). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of AUC(0-infinity) of 36-hydroxymontelukast to Montelukast0.09182 ± 0.0334720.08562 ± 0.036555
SecondaryRatio of Cmax of 5-hydroxyomeprazole to Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of Cmax of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of Cmax of 5-hydroxyomeprazole to Omeprazole0.9461 ± 0.568330.8810 ± 0.49954
SecondaryRatio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (omeprazole) and its metabolite (5-hydroxyomeprazole). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of AUC(0-infinity) of 5-hydroxyomeprazole to Omeprazole1.151 ± 0.664631.077 ± 0.59178
SecondaryRatio of Cmax of 1-hydroxymidazolam to Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of Cmax of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of Cmax of 1-hydroxymidazolam to Midazolam
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of Cmax of 1-hydroxymidazolam to Midazolam0.5286 ± 0.238190.4955 ± 0.20616
SecondaryRatio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam

Blood samples were collected at the indicated time points for pharmacokinetic analysis of parent drug (midazolam) and its metabolite (1-hydroxymidazolam). Ratio of AUC(0-infinity) of metabolite to parent drug has been presented.

Time frame:
Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours post-dose in treatment period 1 and 3
Reported as:
Mean · Ratio
Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam
RatioTreatment A: Probe SubstratesTreatment C: Probe Substrates + GSK3640254 200 mg
Ratio of AUC(0-infinity) of 1-hydroxymidazolam to Midazolam0.4677 ± 0.198530.4618 ± 0.20637

Adverse events

Collected over All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Probe Substrates0/20 (0%)0/20 (0%)1/20 (5%)
Treatment B: GSK3640254 200 mg0/20 (0%)0/20 (0%)5/20 (25%)
Treatment C: Probe Substrates + GSK3640254 200 mg0/19 (0%)0/19 (0%)5/19 (26.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTreatment A: Probe SubstratesTreatment B: GSK3640254 200 mgTreatment C: Probe Substrates + GSK3640254 200 mg
DizzinessNervous system disorders0/203/200/19
HeadacheNervous system disorders1/201/201/19
Taste disorderNervous system disorders0/200/201/19
NauseaGastrointestinal disorders0/201/201/19
Abdominal discomfortGastrointestinal disorders0/200/201/19
Dermatitis contactSkin and subcutaneous tissue disorders0/200/201/19
DiarrhoeaGastrointestinal disorders0/201/200/19
PruritusSkin and subcutaneous tissue disorders0/201/200/19
Rash maculo-papularSkin and subcutaneous tissue disorders0/201/200/19
Rash papularSkin and subcutaneous tissue disorders0/201/200/19

Baseline characteristics

Safety Population consisted of all participants who received at least 1 dose of study medication.

Age, Continuous
Age, Continuous(Years)All Treated Participants
Mean36.4 ± 9.65
Sex: Female, Male
Sex: Female, Male(Participants)All Treated Participants
Female7
Male13
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Treated Participants
Black or African American9
White - Arabic/North African Heritage2
White - White/Caucasian/European Heritage9
08

Study locations

1 site
  • GSK Investigational Site
    Las Vegas, Nevada 89113, United States
09

References and documents

Publications

  • Zhang Y, Johnson M, Joshi S, Yazdani P, Zhan J, Wen B, Bainbridge V, Gartland M, Lataillade M. Open-label, drug-drug interaction study between the HIV-1 maturation inhibitor GSK3640254 and a metabolic probe cocktail in healthy participants. Br J Clin Pharmacol. 2023 Jul;89(7):2236-2245. doi: 10.1111/bcp.15699. Epub 2023 Mar 13. PubMed 36822839 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on ViiV's data sharing criteria can be found at: https://viivhealthcare.com/about-viiv/corporate-ethics-compliance/commitment-to-data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD is made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · viivhealthcare.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Mar 2021, 2 months.

Results were first posted in May 2022, 1 year 2 months after primary completion.

Of 74 industry-sponsored phase 1 interventional studies under HIV Infections, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 18. This study's 2 months is below that.

Counting every sponsor, half of 165 studies reached it within 19 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 11, 2020
StartActual
Dec 16, 2020
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Results first posted
May 23, 2022
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04425902
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Dec 16, 2020
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Results posted
May 23, 2022
Last update
Jan 5, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: GSK3640254 · Metoprolol · Montelukast · Flurbiprofen · Pravastatin

Start the discussion